Barostim Boosts QoL and LVEF, but Mortality Benefit Still Unknown

Strong results from two separate studies on CVRx’s Barostim baroreflex activation therapy suggest the technology might offer symptomatic relief even though its mortality benefit is still up in the air. - Abnormal baroreflex signaling causes neurohormonal issues that drive heart failure progression, so Barostim is intended to help reverse this while combined with GDMT. - The FDA approved Barostim in 2019 based on the BeAT-HF trial which showed improved quality of life and exercise capacity, but..